<SEC-DOCUMENT>0001213900-19-007317.txt : 20190429
<SEC-HEADER>0001213900-19-007317.hdr.sgml : 20190429
<ACCEPTANCE-DATETIME>20190429171227
ACCESSION NUMBER:		0001213900-19-007317
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190423
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190429
DATE AS OF CHANGE:		20190429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wize Pharma, Inc.
		CENTRAL INDEX KEY:			0001218683
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880445167
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52545
		FILM NUMBER:		19777046

	BUSINESS ADDRESS:	
		STREET 1:		5B HANAGAR STREET
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527708
		BUSINESS PHONE:		972 472 260 0536

	MAIL ADDRESS:	
		STREET 1:		5B HANAGAR STREET
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527708

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OphthaliX, Inc.
		DATE OF NAME CHANGE:	20120207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DENALI CONCRETE MANAGEMENT INC
		DATE OF NAME CHANGE:	20030213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k042319_wizepharmainc.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASHINGTON,
D.C. &nbsp;20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURSUANT
TO SECTION 13 OR 15(d) OF THE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report (Date of earliest event reported) April 29, 2019 (April 23, 2019)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Wize
Pharma, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-52545</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>88-0445167</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction
    <BR>
    of Incorporation)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File
    Number)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer <BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24
    Hanagar Street, Hod Hasharon, Israel</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4527708</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal
    Executive Offices)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: &nbsp;<B>+(972) 72-260-0536</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp; &nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp; &nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp; &nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
1.01. Entry into a Material Definitive Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information provided in response to Item 5.02 of this report is incorporated by reference into this Item 1.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2019, the board of directors (the &ldquo;Board&rdquo;) of Wize Pharma, Inc. (the &ldquo;Company&rdquo;) appointed
Mark Sieczkarek as the Company&rsquo;s Chairman of the Board (the &ldquo;Chairman Appointment&rdquo;). Mr. Sieczkarek has
served as Chief Executive Officer of Fe3 Medical Inc. since 2015 and as a director of Orange Twist LLC since 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
2015 through 2018, Mr. Sieczkarek served as Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc., and
continues to serve on its board. He has served as Chief Executive Officer and Chairman of Solta Medical, Inc. from 2006 until
its acquisition by Valeant Pharmaceuticals International, Inc. in 2014. From 2006 to 2014, Mr. Sieczkarek served as Chairman
and Chief Executive Officer of Conceptus, Inc. prior to its acquisition by Bayer Pharmaceuticals. From 1995 to 2003, Mr.
Sieczkarek held multiple roles of increasing responsibility at Bausch &amp; Lomb. He has also held senior executive level
positions with KOS Pharmaceuticals, various subsidiaries of Bristol Myers-Squibb, and Sanofi Diagnostics Pasteur. Mr.
Sieczkarek earned an MBA in Finance from Canisius College in Buffalo, New York and a BS in Accounting from the State
University of New York at Buffalo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Sieczkarek&rsquo;s appointment, the Company and Mr. Sieczkarek entered into a Chairman Agreement (the
&ldquo;Chairman Agreement&rdquo;) whereby Mr. Sieczkarek shall receive 202,399 restricted stock units and options to
purchase 102,222 shares of the Company&rsquo;s common stock at an exercise price of $2.00 per share (the
&ldquo;Chairman Awards&rdquo;). The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and
subsequently in seven equal quarterly installments commencing July 1, 2019</FONT>. The Chairman Agreement has an initial term
of two years (the &ldquo;Term&rdquo;) and provides that in the event of a change of control (as defined in the Chairman
Agreement) the Chairman Awards shall automatically vest in full as of that date. The Chairman Agreement also contains
standard representations and warranties regarding confidential information, non-competition and non-solicitation. The
foregoing is merely a summary of the terms and conditions set forth in the Chairman Agreement, and is qualified in its
entirety by reference to the Chairman Agreement which is attached hereto as <U>Exhibit 10.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of and in connection with the Chairman Appointment, Noam Danenberg (&ldquo;Mr. Danenberg&rdquo;), the current Chairman
of the Board, resigned from the Board and as Chairman and was named Chief Executive Officer. Mr. Danenberg&rsquo;s resignation
was not due in any way to any dispute with the Company and only due to the appointment of Mr. Sieczarek. Since November 7, 2018,
Mr. Danenberg served as the Chairman of the Board, and previously served as the Company&rsquo;s Chief Operating Officer from 2017
to 2018. He has served as a strategic advisor to Wize Pharma Ltd. (&ldquo;Wize Israel&rdquo;), the Company&rsquo;s wholly owned
subsidiary, since April 2015. Mr. Danenberg co-founded Panmed Inc. in January 2014, a company in the field of repositioning drugs
activities. Since 2000, Mr. Danenberg has provided private investment consulting services to numerous private and public companies
through his wholly owned company, N. Danenberg Holding (2000) Ltd. From May 2014 to January 2015, Mr. Danenberg served as a director
of Go.D.M. Investments Ltd. (TASE: GODM). From 2000 to 2012, Mr. Danenberg served as an investment advisor at International Software
Consulting Limited and from 2004 to 2008 he served as the Chairman and CEO of Fitracks Inc. From 2006 to 2012, he also served
as the Chairman of the Board of Hawk Medical Technologies Ltd. Mr. Danenberg holds a B.B.A. in Computer Science from the European
University in Antwerp, Belgium and an M.B.A. from the Boston University Brussels Graduate Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of and in connection with the Chairman Appointment, Or Eisenberg, the Company&rsquo;s Chief Financial Officer and Acting
Chief Executive Officer, resigned from his position as Acting Chief Executive Officer. Mr. Eisenberg&rsquo;s resignation was not
due in any way to any dispute with the Company and he remains Chief Financial Officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01. Other Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2019, the Company issued a press release announcing the Chairman Appointment. A copy of the press release is attached
as <U>Exhibit 99.1</U> hereto and is incorporated herein by reference. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statement and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;No.</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k042319ex10-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman Agreement
    between the Company and Mark Sieczkarek dated as of April 23, 2019 </FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k042319ex99-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated
    as of April 23, 2019 </FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wize Pharma, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 29, 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Or Eisenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Finanncial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f8k042319ex10-1_wizepharma.htm
<DESCRIPTION>CHAIRMAN AGREEMENT BETWEEN THE COMPANY AND MARK SIECZKAREK DATED AS OF APRIL 23, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><B>Exhibit 10.1</B></P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHAIRMAN
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
CHAIRMAN AGREEMENT (&ldquo;Agreement&rdquo;) is entered into between Wize Pharma, Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and Mark Sieczkarek (&ldquo;Mr. Sieczkarek&rdquo;) as of April 23, 2019 to be effective on April 23, 2019 (the &ldquo;Effective
Date&rdquo;). WHEREAS, the Company wishes to engage the services of Mr. Sieczkarek, and Mr. Sieczkarek wishes to accept such an
engagement with the Company, on the terms and conditions set forth herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual agreements contained herein, the Company and Mr. Sieczkarek agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Position and Duties.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company hereby engages Mr. Sieczkarek as the Chairman of the Board of Directors (the &ldquo;Board&rdquo;) of the Company.
As such, Mr. Sieczkarek shall have the responsibilities, duties and authority reasonably expected of a Chairman of the Board,
as more specifically defined in the Bylaws of the Company and as may be further defined by the Board. Mr. Sieczkarek hereby accepts
this engagement upon the terms and conditions herein contained and agrees to devote as much of Mr. Sieczkarek&rsquo;s professional time,
attention, and efforts as necessary to promote and further the business of the Company. Mr. Sieczkarek shall faithfully adhere
to, execute, and fulfill Mr. Sieczkarek responsibilities, duties and authority, and shall comply with all Board directives and
policies established or adopted by the Company. Mr. Sieczkarek shall attend at least one monthly meeting of the Board, review
all press releases and promotional materials as requested by the Board or executive officers of the Company and meet either in
person or telephonically as requested by the executive officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
During the term of this Agreement, Mr. Sieczkarek shall devote as much of Mr. Sieczkarek&rsquo;s energies, interest, abilities,
and productive time to the performance of this Agreement as necessary. However, the Company acknowledges that, subject to Sections
5 and 6 of this Agreement, Mr. Sieczkarek may also render services as a Director of other organizations and as an officer or owner
of any other business, and that the services rendered by Mr. Sieczkarek to the Company shall be part-time only. Specifically,
Mr. Sieczkarek will continue to render commercial and professional services as CEO of Fe3 Medical Inc, a privately held company,
and as a Director of Orange Twist LLC, a privately held company, with full knowledge and approval by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Term and Termination.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Mr. Sieczkarek&rsquo;s engagement under this Agreement shall be for a two (2) year period beginning on the Effective Date and for month
to month thereafter unless and until either party provides written notice thirty (30) days prior to termination of the engagement
(the &ldquo;Engagement Term&rdquo;). In addition, Mr. Sieczkarek&rsquo;s engagement shall be terminable by either party prior to the
end of the Engagement Term as set forth below. Upon the end of the Engagement Term or the effective date of termination, the Company&rsquo;s
obligations to provide Mr. Sieczkarek with Equity Compensation (as defined below) shall end.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall have the right to terminate Mr. Sieczkarek&rsquo;s engagement at any time, without advance notice, upon the following
events, which shall be a &ldquo;Termination for Cause&rdquo;: (i) material breach of any term or condition of this Agreement by
Mr. Sieczkarek; (ii) Mr. Sieczkarek&rsquo;s fraud, breach of trust, dishonesty, misappropriation or similar activity; or (iii) Mr. Sieczkarek&rsquo;s
conviction of any felony or of any other crime involving moral turpitude.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Mr. Sieczkarek shall have the right to terminate Mr. Sieczkarek&rsquo;s engagement at any time, without advance notice, upon a
material breach of any term or condition of this Agreement by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If Mr. Sieczkarek dies during the Engagement Term, this Agreement shall terminate and thereafter the Company shall have no liability
or obligation to Mr. Sieczkarek, Mr. Sieczkarek&rsquo;s heirs, personal representatives, assigns or any other person claiming under
or through Mr. Sieczkarek except for any unvested stock initially granted through this agreement, which stock will become fully
vested as of the date of Mr. Sieczkarek&rsquo;s death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Change of Control</U>. In the event that Mr. Sieczkarek&rsquo;s engagement is terminated in connection with a Change of Control (as
defined below), and this termination is not a Termination for Cause, he shall be entitled to full vesting of the options and restricted
shares issued to him as of that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;Change in Control&rdquo; means the occurrence of any of the following events: (i) any sale or exchange of the capital stock
by the shareholders of the Company in one transaction or series of related transactions where more than 50% of the outstanding
voting power of the Company is acquired by a person or entity or group of related persons or entities; or (ii) any reorganization,
consolidation or merger of the Company where the outstanding voting securities of the Company immediately before the transaction
represent or are converted into less than fifty percent 50% of the outstanding voting power of the surviving entity (or its parent
corporation) immediately after the transaction; or (iii) the consummation of any transaction or series of related transactions
that results in the sale of all or substantially all of the assets of the Company; or (iv) reverse merger; or (v) any &ldquo;person&rdquo;
or &ldquo;group&rdquo; (as defined in the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) becoming the
&ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act) directly or indirectly of securities representing
more than fifty percent (50%) of the voting power of the Company then outstanding; or (vi) less than a majority of the current
Board of Directors are persons who were either nominated for election by the current Board of Directors or were elected by the
current Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If the engagement is terminated without Cause the director shall immediately be entitled to full vesting of the stock granted
up to that date subject to such termination occurred following 180 days as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Compensation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
compensation for Mr. Sieczkarek&rsquo;s services, the Company shall issue Mr. Sieczkarek:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) 202,399 restricted stock units on the Effective Date, with each restricted stock unit representing the right to receive one
share of common stock (equal to 2% of the aggregate shares of common stock outstanding on the Effective Date), which shall
vest in eight equal installments, with the first installment vesting on the Effective Date, and the remaining seven installments
commencing on a quarterly basis commencing July 1, 2019;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Options to purchase 102,222 of the common stock, which options shall have an exercise price of $2.00 per share and shall vest
in eight equal installments, with the first installment vesting on the Effective Date, and the remaining seven installments
commencing on a quarterly basis commencing July 1, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
equity compensation shall be issued under the Company&rsquo;s 2018 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Benefits. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Engagement Term, Mr. Sieczkarek shall be entitled to all ordinary, reasonable and documented out-of-pocket business pre agreed
upon expenses incurred by Mr. Sieczkarek in connection with Mr. Sieczkarek&rsquo;s performance of services for the Company during the
Engagement Term (collectively, &ldquo;Benefits&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Confidential Information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Mr. Sieczkarek recognizes, acknowledges and agrees that he has had and will continue to have access to secret and confidential
information regarding the Company, its subsidiaries and their respective businesses (&ldquo;Confidential Information&rdquo;),
including but not limited to, its products, methods, formulas, patents, sources of supply, customer dealings, data, know-how,
trade secrets and business plans, provided such information is not in or does not hereafter become part of the public domain,
or become known to others through no fault of Mr. Sieczkarek.&nbsp;&nbsp;Mr. Sieczkarek acknowledges that such information is
of great value to the Company, is the sole property of the Company, and has been and will be acquired by his in confidence.&nbsp;&nbsp;In
consideration of the obligations undertaken by the Company herein, Mr. Sieczkarek will not, at any time, during or after his engagement
hereunder, reveal, divulge or make known to any person, any information acquired by him during the course of his engagement, which
is treated as confidential by the Company, and not otherwise in the public domain. The provisions of this <U>Confidentiality Section</U> shall survive the termination of his engagement hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Mr. Sieczkarek affirms that&nbsp;he does not possess and will not rely upon the protected trade secrets or confidential or proprietary
information of any prior employer(s) in providing services to the Company or its subsidiaries.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In the event that his engagement with the Company terminates for any reason, Mr. Sieczkarek shall deliver forthwith to the Company
any and all originals and copies, including those in electronic or digital formats, of Confidential Information; provided, however,
Mr. Sieczkarek shall be entitled to retain (i) papers and other materials of a personal nature, including, but not limited to,
photographs, correspondence, personal diaries, calendars and rolodexes, personal files and phone books, (ii) information showing
his compensation or relating to reimbursement of expenses, (iii) information that he reasonably believes may be needed for tax
purposes and (iv) copies of plans, programs and agreements relating to his engagement, or termination thereof, with the Company.
The covenants and agreements in this <U>Confidentiality Section</U> shall exclude excludes information (A) which is in the public
domain through no unauthorized act or omission of Mr. Sieczkarek or (B) which becomes available to Mr. Sieczkarek on a non-confidential
basis from a source other than Company or its affiliates without breach of such source&rsquo;s confidentiality or non-disclosure
obligations to Company or any of its affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Non-Competition and Non-Solicitation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Sieczkarek acknowledge and agree that the Confidential Information that he has already received and will receive is valuable to
the Company and that its protection and maintenance constitutes a legitimate business interest of the Company, to be protected
by the non-competition restrictions set forth herein. Mr. Sieczkarek acknowledges and agrees that the non-competition restrictions
set forth herein are reasonable and necessary and do not impose undue hardship or burdens on Mr. Sieczkarek. Mr. Sieczkarek also
acknowledges that the time duration set forth in the non-competition restrictions set forth below are reasonable and necessary
to maintain the value of the Confidential Information of, and to protect the goodwill and other legitimate business interests
of, the Company, its affiliates and/or its clients, licensors, licensees or customers. The non-competition and non-solicitation
provisions of this letter agreement shall survive the termination of his engagement hereunder for the time periods specified below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Sieczkarek hereby agrees and covenants that&nbsp;he shall not without the prior written consent of the Company, directly or indirectly,
in any capacity whatsoever, including, without limitation, as an employee, employer, consultant, principal, partner, shareholder,
officer, director or any other individual or representative capacity, or whether on his own behalf or on behalf of any other person
or entity or otherwise howsoever, during his engagement with the Company and thereafter to the extent described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Engage, own, manage, operate, control, be employed by, consult for, participate in, or be connected in any manner with the ownership,
management, operation or control of any business in competition with the Business of the Company, as defined in the next sentence.
For purposes hereof, the Company&rsquo;s &ldquo;Business&rdquo; shall mean as described in the Company&rsquo;s filings with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Recruit, solicit or hire, or attempt to recruit, solicit or hire, any employee, or independent contractor of the Company to leave
the engagement (or independent contractor relationship) thereof, whether or not any such employee or independent contractor is
party to an engagement agreement, for the purpose of competing with the Business of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Attempt in any manner to solicit or accept from any customer, licensor or licensee of the Company, with whom Mr. Sieczkarek had
significant contact during his engagement by the Company (whether under this Agreement or otherwise), business of the kind or
competitive with the business done by the Company with such customer, licensor or licensee or to persuade or attempt to persuade
any such customer, licensor or licensee to cease to do business or to reduce the amount of business which such party has customarily
done or might do with the Company, or if any such party elects to move its business to a person other than the Company, provide
any services of the kind or competitive with the business of the Company for such party, or have any discussions regarding any
such service with such party, on behalf of such other person for the purpose of competing with the Business of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Interfere with any relationship, contractual or otherwise, between the Company and any other party, including, without limitation,
any supplier, distributor, co-venturer or joint venturer of the Company, for the purpose of soliciting such other party to discontinue
or reduce its business with the Company for the purpose of competing with the Business of the Company.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the activities described in Paragraphs (a), (b), (c) and (d) above, the restrictions of this <U>Non-Competition and
Non-Solicitation Section</U> shall continue during the Engagement Term and for a period of three years thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Contents of Agreement; Amendment and Assignment. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement sets forth the entire understanding between the parties hereto with respect to the subject matter hereof and supersedes
all prior agreements, understandings, or representations between the parties. This Agreement cannot be changed, modified or terminated
except upon written amendment duly executed by the parties hereto. All of the terms and provisions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective heirs, personal representatives, successors and
assigns of the parties hereto, except that (a) the duties and responsibilities of Mr. Sieczkarek hereunder are of a personal nature
and shall not be assignable in whole or in part by Mr. Sieczkarek and (b) the rights and interests of Mr. Sieczkarek hereunder
shall not be assignable in whole or in part by Mr. Sieczkarek.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Severability.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
an arbitrator or court of competent jurisdiction holds that any provision of this Agreement is void or unenforceable, the remaining
provisions shall continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Notices.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any notice under this Agreement given by the Company to Mr. Sieczkarek shall be personally delivered to Mr. Sieczkarek or sent
by certified mail to Mr. Sieczkarek&rsquo;s most recent home address as shown in the Company&rsquo;s records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any notice by Mr. Sieczkarek to the Company shall be sent by certified mail to the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wize
Pharma, Inc.</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24 Hanagar Street&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hod
Hasharon, Israel</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4527708&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Any notice sent by certified mail shall be effective when mailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Applicable Law.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
Agreement shall be governed for all purposes by the internal laws of the State of New York, without reference to the conflict
of laws provisions of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Board of Directors&rsquo; Approval.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
Agreement is subject to and conditioned upon the approval of the Company&rsquo;s Board which, by signatures of its authorized
officer hereon, is hereby confirmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Wize Pharma, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>/s/
Or Eisenberg</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>/s/
Mark Sieczkarek</P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or
Eisenberg</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Sieczkarek</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>f8k042319ex99-1_wizepharma.htm
<DESCRIPTION>PRESS RELEASE DATED AS OF APRIL 23, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Wize Pharma Appoints Mark Sieczkarek
as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HOD HASHARON,&nbsp;Israel, April 23, 2019 /PRNewswire/ --&nbsp;<B>Wize
Pharma, Inc.</B>&nbsp;(&ldquo;Wize Pharma&rdquo; or the &ldquo;Company&rdquo;) (OTCQB: WIZP) a clinical-stage biopharmaceutical company
focused on the treatment of&nbsp;ophthalmic disorders, is pleased to announce that Mr. Mark Sieczkarek has been appointed Chairman
of Wize Pharma&rsquo;s Board of Directors, replacing Mr. Noam Danenberg, who will become the Company&rsquo;s Chief Executive Officer, effective
April 23, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Sieczkarek has more than 39 years of leadership experience
in the medical industry, including from 2006 to 2014 as CEO and Chairman of the Board of Solta Medical. Prior to its acquisition
by Valeant Pharmaceuticals International, and from 2003 to 2011 as President and CEO of Conceptus, prior to its acquisition by
Bayer Pharmaceuticals.&nbsp;From 1995 to 2003, Mr. Sieczkarek held multiple roles of increasing responsibility at Bausch &amp;
Lomb (&ldquo;B&amp;L&rdquo;), ultimately becoming Senior Vice President and President of the Americas region, where he was responsible
for the commercial operation of all B&amp;L businesses in the United States, Canada, and Latin America. He also served as President
of the European region. Mr. Sieczkarek also held senior executive level positions with KOS Pharmaceuticals, several Bristol Myers-Squibb
subsidiaries, and Sanofi Diagnostics Pasteur.&nbsp; Mr. Sieczkarek earned an MBA in Finance from Canisius College in Buffalo, New
York and a BS in Accounting from the State University of New York at Buffalo. He also was past Chairman and CEO of NovaBay Pharma
and continues to serve there as a Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are fortunate to have Mark Sieczkarek, with his experience
and expertise, join Wize Pharma as Chairman of the Board. &nbsp;I don&rsquo;t believe there is a better-suited person for this role and
Mark&rsquo;s taking over as Chairman could not come at a more auspicious time for the Company and our shareholders. Mark&rsquo;s four decades
of industry experience in combination with strong investor relationships will be invaluable as we seek greater visibility in the
U.S.,&rdquo; said Noam Danenberg, Wize Pharma&rsquo;s Chief Executive Officer.&nbsp; &ldquo;We look forward to his guidance as we advance
our current clinical programs and expand our pipeline through opportunistic acquisitions and/or licensing of new ophthalmic products.&nbsp;
Personally, I greatly look forward to my new role as Chief Executive Officer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Wize Pharma represents an exciting commercial and business
opportunity, and I am extremely pleased to join the Company as Chairman,&rdquo; commented Mr. Sieczkarek.&nbsp; &ldquo;Eye health
has long been an area of my professional focus, and I look forward to contributing to the development of this growing company as
we strengthen our position in the U.S. and certain global markets.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Wize Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;&nbsp;</B><BR>
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including
DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for
the treatment of DES, and other ophthalmological illnesses, including CCh and Sj&ouml;gren&rsquo;s syndrome (Sj&ouml;gren&rsquo;s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LO2A is currently registered and marketed by its inventor in
Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and Sj&ouml;gren&rsquo;s and in the Netherlands
for the treatment of DES and Sj&ouml;gren&rsquo;s. Wize&rsquo;s strategy involves engaging local or multinational distributors to handle the
distribution of LO2A. Wize has finished a Phase II trial of LO2A for patients with CCH and is currently conducting a Phase IV study
for LO2A for DES in patients with Sj&ouml;gren&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><BR>
Wize cautions you that statements in this press release that are not a description of historical fact are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the
use of words referencing future events or circumstances such as &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; and &ldquo;will,&rdquo; among others. For example, when we discuss our market potential, we are using a forward-looking
statement. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed
or implied by such forward-looking statements. These forward-looking statements are based upon Wize&rsquo;s current expectations and
involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include,
without limitation, the possibility that we will not be able to successfully operate our joint venture with Cannabics Pharmaceuticals,
Inc.; risks related to the substantial debt that we have incurred; our needs for additional financing; our dependence on a single
compound, LO2A and on the continuation of our license to commercialize LO2A; our inability to expand our rights under our license
of LO2A; the initiation, timing, progress and results of our trials and product candidate development efforts; our ability to advance
LO2A into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals
for LO2A, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance
of LO2A; our ability to establish and maintain corporate collaborations; the implementation of our business model and strategic
plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property
rights covering LO2A and our ability to operate our business without infringing the intellectual property rights of others; estimates
of our expenses, future revenues, and capital requirements; competitive companies, technologies and our industry; and statements
as to the impact of the political and security situation in Israel on our business. More detailed information about the risks and
uncertainties affecting Wize is contained under the heading &ldquo;Risk Factors&rdquo; included in Wize&rsquo;s Annual Report on Form 10-K
filed with the SEC on April 1, 2019 Registration Statement on Form S-1 filed with the SEC on February 6, 2018, and in other filings
that Wize has made and may make with the SEC in the future. You are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the date on which they were made. Wize does not undertake any obligation to update such statements to reflect
events that occur or circumstances that exist after the date on which they were made, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For all Inquiries, please contact:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
Or Eisenberg<BR>
Chief Financial Officer<BR>
+972-72-260-0536<BR>
or@wizepharma.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$ 9 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MST6S!7ME+09 XPQZY.?XW_\ @E;\+#\4_P!MWX1I<6\D^C_#C^VOBSK!,0Q
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M3]#TK3-"TRWCL],TFPM=,T^TCP8(=.L;=;2RMU!ZJEG BC/3:,D]#KT5YO\
M%GXAZ3\)_A?\1OB?K;1QZ1\._ _BSQOJ;2/Y*BR\+Z#?:W=#<1U:.R89]6SD
MGK_(<8SJ5(PBI3J5:D8Q6\IU*LU"*\W*<XQ\KW/T!M13DW913;?9+=G\,O\
MP5@^,H^+G[?/Q\OK:Y\_2/ >O:;\)M&\N07$$-O\,M*.C:V;0+P2?%][XE8D
M<$DD'O7YXI?]?P[?Y_S^-<GK7C#5?%6N:YXJUN:2XUSQ1K.I>)-9EEE'[[6_
M$^K7NM:UT'0W]Y>?A^%5TO\ K\_I_GK]:_JG+Z7U# X/!0:<<)A</ATXOW7[
M"E&EIOVG*W3VEKOEN_A:\W5K5*DMYSE)^7-)SM?K;FM?K:_D>B1W_3#^N/\
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M^Q;\;]:ANTM-5\0^';?X?:*6 W2:G\0=4L_"Y"@#@IIU_JM^3QD6; GG!_C
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M^SIX;N;:.XT?POXLN?BUXC\V+[1;_P!G?#&T_P"$GL_MF3@_VGXML_#>F_\
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M5>LE!4J:C252+DG+VDN?6*5.$W'EO*UTC]5=Z^OZ'_"G5_,]^Q!?_P#!0_\
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ME.G976U2,6_2W4Z*B;A))7;32Z;G^2&NI%_G_P _X_7OZ^M7$O\ K^';_/\
MG\:_T//^(.3]@3_HY#]LC_P?_!'_ .<[3Q_P9T?L#CK^TE^V1C_L/?!(8_+X
M._TK[=<1Y:MZE5_]P*B_0XWAIO;D7_;S?Z'\W7_!M+\!V^/W_!6'X+ZQ>6,F
MH>&OV>/"7C[]H/7>0MO9:EX:TH>"?!>"<G=_PGOCW1]2 [MH87C(-?ZEJC:
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M4+0]I@JV%JU_>]WDI0Q$9\CM[TOWR<8Z7L]5?3X&_P"#@'_DQ33?^RY^!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
